OcugenUS67577C1053OCGNOCGN
Financials
Market Cap
$338.71M5Y beta
3.51EPS (TTM)
-$0.262Free Float
253.60MRevenue (TTM)
$6.04MEBITDA (TTM)
-$64.83MFree Cashflow (TTM)
-$72.53MPricing
Analyst Ratings
The price target is $5.333 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.